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•	Hemophagocytic lymphohistiocytosis
(HLH) is an immune system disorder
with aberrant activation of T cells
and macrophages resulting in
vast tissue destruction. There
are two forms of HLH: inherited
HLH (autosomal recessive) and
secondary HLH, occurring after
strong immunologic activation.
•	Primary HLH results from defective
proteins involved in the cytolytic
secretory pathway. These defective
proteins prevent cytotoxic T
lymphocytes and Natural Killer (NK)
cells from maintaining immune
homeostasis.
•	In contrast, secondary HLH
results from upregulation of
proinflammatory cytokines which
results in overactivation of T
lymphocytes and NK cells. However,
the end result of both primary and
secondary HLH is the same; cellular
death and organ failure.
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•	A 56 y.o. female with a history of Essential thrombocytosis (ET) s/p hydroxyurea treatment
presented to the ED with an episode of gross hematuria. She was hypertensive and febrile.
Physical exam was significant for petechiae on all extremities, tachycardia, diffuse abdominal
tenderness, and splenomegaly.
•	Considering patient’s history of ET, which has a predisposition to progress to Acute Myeloid
Leukemia, and long term exposure to hydroxyurea (a leukemogenic agent) suspicion for leukemia
was very high.
•	However, a low fibrinogen level indicated DIC. It wasn’t clear as to whether the DIC resulted from
bacteremia or acute promyelocytic leukemia (APL), a variant of AML known to precipitate DIC. As
such, a bone marrow biopsy was conducted for further analysis.
•	However, cytogentic testing failed to reveal (15; 17) translocation; which, as a result, ruled out APL.
•	With findings of hypercellularity and increased levels of myleoblasts in the bone marrow, a
diagnosis of AML was made.
•	A closer re-examination of bone marrow biopsy revealed histiophagocytic behavior (Figure D).
Such morphological presentation raised the suspicion for HLH. As such, ferritin and triglyceride
levels were ordered which revealed a level of >12,000 and 226, respectively.
•	A diagnosis of HLH was made considering negative blood cultures, biopsy findings, hyperferritinemia and hypofibrinoginemia.
•	Pt was started on HLH-94 Protocol along with idarubicin and cytarabine for AML induction therapy.
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FOLLOW-UP:
•	Patient was started on HLH-94 Protocol (etoposide
and tapering steroids) along with idarubicin and
cytarabine; subsequently platelets increased to
37,000 and both ferritin and fibrinogen normalized.
•	Upon stabilization, pt was discharged and scheduled
for follow up by Hematology Oncology at Penn State
University for bone marrow transplant.
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•	This presentation illustrates a transformation of
ET into AML with concurrent HLH; highlighting the
importance of considering HLH in AML patients
presenting with DIC, as early detection could be
essential in managing both patients’ malignancy and
hemodynamic status.
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Figure A. The bone marrow biopsy is noted to
be hypercellular. With progression of age, bone
marrow is gradually replaced with adipose tissue.
Considering patient’s age, approximately 20-30% of
her bone marrow should be adipose. Presentation is
suggestive of leukemia.

Figure B. Under magnification. Arrows
point to myleoblasts. Suggestive of
acute myeloblastic leukemia (AML).

Figure C. Anti-CD34 Stain. This stain
tests for CD34, a cell surface protein
found on myleoblasts.

Figure D. Arrows point to macrophages
phagocytosing neutrophils; note the large
vacuoles. Though not pathognomonic,
such activity is suggestive of hemophagocytic lymphohistiocytosis.

